Human Umbilical Cord Mesenchymal Stem Cells

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Human Umbilical Cord Mesenchymal Stem Cells
Accession Number
DB15726
Description

Stem cells obtained from amniotic fluid, the umbilical cord (UC), and placenta are gaining in popularity. Stem cells from the umbilical cord offer several advantages, including: non-invasive collection procedures, more hearty and steady growth than bone-marrow derived stem cells (they can maintain a steady doubling time (DT) over up to 10 passages), higher differentiation capability, and faster self-renewal. These cells express low levels of major histo-compability complex (MHC) class I, and generally lack MHC class II and its co-stimulatory ligands like CD40, CD80, and CD86. Thus, they are characterized with low immunogenicity. The umbilical cord, which starts developing in the fifth week of gestation, contains different compartments where stem cells originate: the cord lining, Wharton’s jelly, and perivascular region.

UC mesenchymal cells derived from Wharton’s jelly are the most studied and offer more stable and better osteogenic and adipogenic differentiation potentials. The cells are extracted by either the explant or the enzymatic digestion method, though neither method has been characterized as the ‘standard’ thus far. The explant method requires manual mincing of the tissue fragments and results in an inconsistent number of extracted MSCs. In contrast, the enzymatic digestion method uses enzymes to break down the non-required cell fragments, and results in more consistent cell numbers. Regardless of extraction method, the cells are usually expanded in vitro in laboratories using culture systems and bioreactors.

The cord lining of the UC is generally isolated with the explant method -- resulting in two kinds of MSCs: cord lining mesenchymal stem cells (CLMC), which are used to aid in burn and diabetic ulcer wound healing, and cord lining epithelial stem cells (CLEC), which are used for persistent corneal epithelial defects and skin improvements.

Currently many companies are creating their own version of these stem cells, one of which is by Aspire, who are creating a version named ACT-20.

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
  • HUCMSCs
  • Human Umbilical Cord Wharton’s Jelly-derived Mesenchymal Stem Cells
  • Mesenchymal Stromal Cells
  • UC-MSCs
  • WJ-MSCs
  • XCEL-UMC-BETA
External IDs
  • ACT-20
  • Human Umbilical Cord Mesenchymal Stem Cells

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

General theories of therapeutic action postulate that HUCMSCs can replace damaged cells, inhibit immunological functions through paracrine actions, and promote proliferation of endogenous stem cells through cell-cell communication. HUCMScs are thought to alter immune function through inhibition of Natural Killer Cell, T-cell, and B-cell proliferation along with redirecting monocytes and dendritic cells to less mature states. HUCMSCs are currently investigated for specific cell-based therapies, as they can be differentiated and engrafted for various disease states with low immunogenicity. Such applications include neurodegenerative diseases, spinal cord injury, stroke, and even liver disease. Certain factors secreted by HUCMSCs, such as oxidative stress pathways, are also thought to inhibit tumor growth and even lymphoma cell growth. These therapies are currently being considered for the treatment of COVID-19.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Ding DC, Chang YH, Shyu WC, Lin SZ: Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24(3):339-47. doi: 10.3727/096368915X686841. Epub 2015 Jan 23. [PubMed:25622293]
  2. Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, Troyer D, McIntosh KR: Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells. 2008 Nov;26(11):2865-74. doi: 10.1634/stemcells.2007-1028. Epub 2008 Aug 14. [PubMed:18703664]
  3. Li T, Xia M, Gao Y, Chen Y, Xu Y: Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin Biol Ther. 2015;15(9):1293-306. doi: 10.1517/14712598.2015.1051528. Epub 2015 Jun 12. [PubMed:26067213]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentChronic Graft Versus Host Disease1
2Active Not RecruitingTreatmentFibrosis / Kidney Transplant Rejection1
2Active Not RecruitingTreatmentMSC / Osteoarthritis (OA) / Stem Cells1
2Active Not RecruitingTreatmentPremature Ovarian Failure (POF)1
2CompletedTreatmentChronic Ischemic Heart Disease1
2CompletedTreatmentCongenital Hypoplastic Anemia / Sickle Cell Disease (SCD) / Thalassaemic disorders1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2CompletedTreatmentRespiratory Distress Syndrome, Adult1
2Enrolling by InvitationTreatmentChronic Heart Failure (CHF) / Non-ischaemic Cardiomyopathy / Non-ischemic Dilated Cardiomyopathy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 11, 2020 12:37 / Updated on August 13, 2020 01:02

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates